Clinical use of ruxolitinib in an academic medical center in unselected patients with myeloproliferative neoplasms not on clinical study

Leukemia and Lymphoma

Volumn 58, Issue 4, 2017, Pages 866-871

  Naqvi, Kiran ^a   Daver, Naval ^a   Pemmaraju, Naveen ^a   Bose, Prithviraj ^a   Garcia Manero, Guillermo ^a   Cortes, Jorge ^a   Kantarjian, Hagop M ^a   Verstovsek, Srdan ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Myelofibrosis; myeloproliferative neoplasms; ruxolitinib; splenomegaly

Indexed keywords

2 [1 (4 FLUOROPHENYL)ETHYLAMINO] 4 (1 METHYL 1H PYRAZOL 4 YL) 6 (2 PYRAZINYLAMINO)PYRIDINE; ANAGRELIDE; AZACITIDINE; CYTARABINE; DANAZOL; DECITABINE; GANDOTINIB; HEMOGLOBIN; HYDROXYUREA; IMMUNOMODULATING AGENT; MOMELOTINIB; N,N DICYCLOPROPYL 4 [(1,5 DIMETHYL 1H PYRAZOL 3 YL)AMINO] 6 ETHYL 1,6 DIHYDRO 1 METHYLIMIDAZO[4,5 D]PYRROLO[2,3 B]PYRIDINE 7 CARBOXAMIDE; PACRITINIB; RUXOLITINIB; ANTINEOPLASTIC AGENT; JANUS KINASE 2; PROTEIN KINASE INHIBITOR; PYRAZOLE DERIVATIVE;

ACUTE MYELOID LEUKEMIA; ADD ON THERAPY; ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER FATIGUE; CANCER SURVIVAL; CARDIOPULMONARY INSUFFICIENCY; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL STUDY; CLONAL EVOLUTION; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; ERYTHROCYTE CONCENTRATE; ERYTHROCYTE TRANSFUSION; FEMALE; FEVER; FOLLOW UP; HEALTH INSURANCE; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HUMAN; LOW DRUG DOSE; MALE; MALIGNANT TRANSFORMATION; MEDICAL RECORD REVIEW; MIDDLE AGED; MYELOFIBROSIS; MYELOID METAPLASIA; MYELOPROLIFERATIVE NEOPLASM; NIGHT SWEAT; OVERALL SURVIVAL; POLYCYTHEMIA; POLYCYTHEMIA VERA; PRIORITY JOURNAL; QUALITY OF LIFE; SIDE EFFECT; SPLEEN SIZE; SPLENOMEGALY; STEM CELL TRANSPLANTATION; SUBDURAL HEMATOMA; THROMBOCYTE COUNT; THROMBOCYTHEMIA; THROMBOCYTOPENIA; UNIVERSITY HOSPITAL; ANTAGONISTS AND INHIBITORS; GENETICS; MUTATION; MYELOPROLIFERATIVE DISORDER; TREATMENT OUTCOME; VERY ELDERLY;

ACADEMIC MEDICAL CENTERS; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; JANUS KINASE 2; MALE; MIDDLE AGED; MUTATION; MYELOPROLIFERATIVE DISORDERS; PROTEIN KINASE INHIBITORS; PYRAZOLES; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 84982786659     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428194.2016.1217528     Document Type: Article

References (24)

1. Tefferi A, Vardiman JW., Classification and diagnosis of myeloproliferative neoplasms:the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia. 2008;22:14–22.
2. Barosi G, Mesa RA, Thiele J, et al. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis:a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia. 2008;22:437–438.
3. Tefferi A, Vaidya R, Caramazza D, et al. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis:a comprehensive cytokine profiling study. J Clin Oncol. 2011;29:1356–1363.
4. Mesa RA, Silverstein MN, Jacobsen SJ, et al. Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia:an Olmsted County Study, 1976-1995. Am J Hematol. 1999;61:10–15.
5. Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113:2895–2901.
6. Orazi A, Germing U., The myelodysplastic/myeloproliferative neoplasms:myeloproliferative diseases with dysplastic features. Leukemia. 2008;22:1308–1319.
7. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signaling causes polycythemia vera. Nature. 2005;434:1144–1148.
8. Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366:799–807.
9. Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366:787–798.
10. Geyer H, Cannon K, Knight E, et al. Ruxolitinib in clinical practice for therapy of myelofibrosis:single USA center experience following Food and Drug Administration approval. Leukemia Lymphoma. 2014;55:195–197.
11. Chen YY, Huang CE, Lee KD, et al. Clinical efficacy and safety of ruxolitinib in the management of myelofibrosis:a single institution experience in Taiwan. Hematology. 2016;21:3–9.
12. Ellis MH, Lavi N, Mishchenko E, et al. Ruxolitinib treatment for myelofibrosis:efficacy and tolerability in routine practice. Leukemia Res. 2015;39:1154–1158.
13. Tefferi A, Cervantes F, Mesa R, et al. Revised response criteria for myelofibrosis:International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. Blood. 2013;122:1395–1398.
14. Passamonti F, Cervantes F, Vannucchi AM, et al. Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis. Blood. 2010;116:2857–2858.
15. Kremyanskaya M, Mascarenhas J, Rampal R, et al. Development of extramedullary sites of leukemia during ruxolitinib therapy for myelofibrosis. Br J Haematol. 2014;167:144–146.
16. Eghtedar A, Verstovsek S, Estrov Z, et al. Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia. Blood. 2012;119:4614–4618.
17. Pemmaraju N, Kantarjian H, Kadia T, et al. A phase I/II study of the Janus kinase (JAK)1 and 2 inhibitor ruxolitinib in patients with relapsed or refractory acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2015;15:171–176.
18. Quintás-Cardama A, Tong W, Kantarjian H, et al. A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis. Leukemia. 2008;22:965–970.
19. Mesa RA, Verstovsek S, Rivera C, et al. 5-Azacitidine has limited therapeutic activity in myelofibrosis. Leukemia. 2009;23:180–182.
20. Thepot S, Itzykson R, Seegers V, et al. Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine:a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM). Blood. 2010;116:3735–3742.
21. Mascarenhas J, Navada S, Malone A, et al. Therapeutic options for patients with myelofibrosis in blast phase. Leukemia Res. 2010;34:1246–1249.
22. Badar T, Kantarjian HM, Ravandi F, et al. Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase. Leukemia Res. 2015;39:950–956.
23. Tabarroki A, Saunthararajah Y, Visconte V, et al. Ruxolitinib in combination with DNA methyltransferase inhibitors:clinical responses in patients with symptomatic myelofibrosis with cytopenias and elevated blast(s) counts. Leukemia Lymphoma. 2015;56:497–499.
24. Mwirigi A, Galli S, Keohane C, et al. Combination therapy with ruxolitinib plus 5-azacytidine or continuous infusion of low dose cytarabine is feasible in patients with blast-phase myeloproliferative neoplasms. Br J Haematol. 2014;167:714–716.